ArticleMolecular therapy. Nucleic acids2026
Identification and diagnostic evaluation of an aptamer targeting prostate-cancer-derived small extracellular vesicles.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomaterial-Enabled Fiber-Optic SPR Biosensor for Continuous and Noninvasive Body Fluid Monitoring:Progress and Prospects.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) lacks convenient, non-invasive, and highly specific diagnostic markers. Aptamers have emerged as preferred probes for biosensors that target extracellular vesicles (EVs). This study aimed to explore the diagnostic value of PCa-specific EVs aptamer probes. We used EV-SELEX to identify aptamers that selectively target PCa small EVs (sEVs). Surface plasmon resonance (SPR) and nanoflow cytometry were used to verify aptamer affinity. The diagnostic value of PCa was evaluated using clinical samples from patients. We screened and validated an aptamer, seq25, which exhibited high specificity for PCa-derived sEVs. The SPR assay revealed a strong binding affinity, with a KD of 24.02 nM and a dose-dependent binding response. Nanoflow cytometry demonstrated that seq25 could distinguish sEVs from PCa and normal prostate cell lines. In clinical specimens, the proportion of seq25-positive sEVs isolated from urine samples was significantly higher in patients with PCa than in those with benign prostatic hyperplasia. Our study integrated the diagnostic advantages of EVs with the technical benefits of aptamers to develop a PCa-specific sEVs aptamer probe that offers a promising non-invasive approach for PCa diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.